Cornercap Investment Counsel Inc. Makes New Investment in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Cornercap Investment Counsel Inc. purchased a new stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) in the 4th quarter, Holdings Channel.com reports. The institutional investor purchased 4,208 shares of the specialty pharmaceutical company’s stock, valued at approximately $518,000.

Several other large investors have also recently modified their holdings of the stock. Charles Schwab Investment Management Inc. lifted its position in Jazz Pharmaceuticals by 8.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 531,710 shares of the specialty pharmaceutical company’s stock valued at $59,238,000 after acquiring an additional 42,587 shares in the last quarter. Cerity Partners LLC boosted its holdings in shares of Jazz Pharmaceuticals by 128.4% in the third quarter. Cerity Partners LLC now owns 32,757 shares of the specialty pharmaceutical company’s stock worth $3,650,000 after buying an additional 18,414 shares during the last quarter. Townsquare Capital LLC bought a new stake in Jazz Pharmaceuticals during the third quarter valued at approximately $220,000. Fiduciary Trust Co boosted its stake in shares of Jazz Pharmaceuticals by 49.6% during the 3rd quarter. Fiduciary Trust Co now owns 6,770 shares of the specialty pharmaceutical company’s stock worth $754,000 after acquiring an additional 2,246 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Jazz Pharmaceuticals by 17.0% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,899 shares of the specialty pharmaceutical company’s stock worth $1,326,000 after purchasing an additional 1,729 shares during the period. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Wall Street Analysts Forecast Growth

JAZZ has been the subject of several recent research reports. Royal Bank of Canada cut their price target on Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating for the company in a report on Wednesday, February 26th. Morgan Stanley reaffirmed an “overweight” rating and set a $183.00 price target (up previously from $175.00) on shares of Jazz Pharmaceuticals in a report on Friday, March 7th. Wells Fargo & Company upgraded shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $130.00 to $170.00 in a research report on Thursday, February 13th. JPMorgan Chase & Co. increased their price target on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Finally, Truist Financial boosted their price objective on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research report on Thursday, March 6th. One equities research analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $187.71.

Jazz Pharmaceuticals Trading Down 2.8 %

Shares of NASDAQ JAZZ opened at $122.92 on Friday. The stock has a market capitalization of $7.47 billion, a P/E ratio of 17.31, a PEG ratio of 1.04 and a beta of 0.44. Jazz Pharmaceuticals plc has a 1-year low of $99.06 and a 1-year high of $148.06. The business’s 50 day moving average is $132.30 and its two-hundred day moving average is $122.54. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74.

Insider Activity

In related news, CAO Patricia Carr sold 1,140 shares of the business’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $137.81, for a total transaction of $157,103.40. Following the completion of the transaction, the chief accounting officer now owns 7,012 shares in the company, valued at $966,323.72. The trade was a 13.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Neena M. Patil sold 3,800 shares of Jazz Pharmaceuticals stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $144.87, for a total value of $550,506.00. Following the sale, the executive vice president now owns 33,318 shares of the company’s stock, valued at approximately $4,826,778.66. This trade represents a 10.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 28,736 shares of company stock valued at $4,022,825. 4.20% of the stock is currently owned by insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.